These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30691343)

  • 1. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care.
    Reid TS; White J; Meneghini L
    J Fam Pract; 2019 Jan; 68(1 Suppl):. PubMed ID: 30677105
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degludec: a novel basal insulin.
    Kalra S; Baruah MP; Niazi AK
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the pharmacological properties of insulin degludec and their clinical relevance.
    Haahr H; Heise T
    Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The past, present, and future of basal insulins.
    Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
    Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.
    Arnolds S; Kuglin B; Kapitza C; Heise T
    Int J Clin Pract; 2010 Sep; 64(10):1415-24. PubMed ID: 20618882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
    Heise T; Nosek L; Bøttcher SG; Hastrup H; Haahr H
    Diabetes Obes Metab; 2012 Oct; 14(10):944-50. PubMed ID: 22726241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.
    Gilor C; Culp W; Ghandi S; do Carmo Emidio E Silva JA; Ladhar A; Hulsebosch SE
    Domest Anim Endocrinol; 2019 Oct; 69():19-29. PubMed ID: 31280022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.
    Drab SR; Philis-Tsimikas A
    Pharmacotherapy; 2014 Mar; 34(3):291-302. PubMed ID: 24132869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of basal insulins.
    Porcellati F; Bolli GB; Fanelli CG
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Clinical Profile of IDegAsp.
    Unnikrishnan AG; Singh AK; Modi KD; Saboo B; Garcha SC; Rao PV
    J Assoc Physicians India; 2015 May; 63(5 Suppl):15-20. PubMed ID: 26548030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmet needs in children with diabetes: the role of basal insulin.
    Tumini S; Carinci S
    Minerva Pediatr; 2017 Dec; 69(6):513-530. PubMed ID: 29181962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.